Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 12, 2026

China’s $3 Trillion of Hidden Bad Debt Prolongs Economic Pain

View original at finance.yahoo.com
“By any measure, Tom Hu should be in default on a $730,000 bank loan for his plastics business in China.”
Verbatim excerpt from the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Chinese economy is getting worse and many businesses are struggling; banks and borrowers both have incentives to hide bad debt to avoid credit blacklists and rising NPL disclosures

    60% confidence
  • China's banking leniency threatens to become a permanent drag on the world's second-largest economy by recycling capital into unproductive companies rather than productive ones

    60% confidence
  • China's official non-performing loan ratio is 1.5%

    60% confidence
  • There is no financial crisis, but there is no free lunch in economics. The price of China's loan forbearance is slower growth, inefficiency, and low productivity

    60% confidence
  • Some analysts believe China's hidden bad debt could be double the $3 trillion estimate, implying up to $6 trillion in disguised non-performing loans

    60% confidence
  • China's true bad loan ratio is approximately 10%, implying roughly $3 trillion in loans that should be classified as past due are not

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com